# NCT05113251 (NCT05113251)

> Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05113251
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Breast Neoplasms; Breast Cancer; HER2-positive Early Breast Cancer
- Interventions: Trastuzumab Deruxtecan; Paclitaxel; Trastuzumab; Pertuzumab; Doxorubicin; cyclophosphamide
- Enrollment: 927
- Primary outcome: Rate of Pathologic Complete Response (pCR).

## Commentary we found

- X threads: 84
- YouTube: 81
- Podcasts: 51
- X videos: 8

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct05113251

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05113251", "email": "<work email>"}; the inbox owner confirms by the emailed link.